WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. Background: Tenosynovial giant cell tumor (TGCT) ...
Don’t tell Neil Armstrong, but giant leaps for mankind may leave astronauts feeling a little queasy. In a new experiment, aerospace engineers at the University of Colorado Boulder will work with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results